About Us

Dr Shahab Asgharzadeh founded Simurx to address persistent inefficiencies in solid tumor therapy and improve patient outcomes using innovative solutions. He brings decades of experience working with various cancer therapeutic modalities to his role as chief executive officer where he is focused on facilitating Simurx’s innovation and endeavor for advanced cancer treatments.

Dr Asgharzadeh has a BS degree in Biomedical engineering from Northwestern University and an MD degree from the University of Chicago. He is a board certified in pediatrics and in pediatric Hematology Oncology and he is an attending physician at the department of Hematology, Oncology and Blood and Marrow transplantation at Children’s Hospital Los Angeles. Shahab is an Associate Professor at the University of Southern California and is the Director of the Neuroblastoma Basic and Translational Program.

Shahab’s research uses genetic and translational biomarkers to identify signatures in the tumor and its microenvironment. Those signatures are used to predict patient outcome and to identify ways by which the behavior of the tumor microenvironment can be reversed so that immune system cells can get rid of the tumor. Some interventions designed by his lab include Bispecific T cell engager (BiTEs) and Chimeric Antigen Receptors (CARs).